{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113740","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.674068+00:00","generated_at":"2026-05-30T17:17:11.761734+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Alkermes hosts investor event to review orexin portfolio and development strategy","bullets":["Presentation reviewed Alkermes' orexin portfolio on October 9, 2024.","No specific financial or clinical data disclosed in the furnished exhibit.","Investor event focused on development strategy for orexin programs.","Filing under Item 7.01 (Regulation FD) with presentation as Exhibit 99.1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113740","json":"https://secwatch.observer/filing/0000950170-24-113740.json","markdown":"https://secwatch.observer/filing/0000950170-24-113740.md","text":"https://secwatch.observer/filing/0000950170-24-113740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024113740/0000950170-24-113740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024113740/alks-20241009.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:17:11.761734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}